1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Biosimilar Monoclonal Antibodies Market Forecast 2016-2026: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

  • February 2016
  • 203 pages
  • Visiongain
Report ID: 3748601

Summary

Table of Contents

Please note: The license is valid for 12 months from the date the report is sent.


Report Details
You need a single report that pulls together best practice, forecasts, primary research and sales figures of biosimilar monoclonal antibodies all in one place. This report provides you with that vital information and it does it, today.

Our new report discusses issues and events affecting the biosimilar monoclonal antibody market.

You will find discussions, including qualitative analyses on:
- Patent expiries and how they will affect the market
- Newly published guidelines on biosimilarity by the Chinese FDA and the US FDA
- The challenges facing the market, including the complexity of the molecules and the use of biobetters
- How demand in emerging markets for cheap drugs will fuel demand
- How clinician and patient confidence in biosimilar monoclonal antibodies will affect the rate of adoption

Convergence and co-ordination of regulatory guidelines between national markets will help to clarify what manufacturers need to do in order to get their products released across multiple market places. Unified global guidelines will also help to prevent market fragmentation, as is the case at present in India. Many biosimilar mAbs have been released here as the regulatory guidelines are not as stringent as those in more developed markets. Demand will be fuelled by the need for cheaper drugs as healthcare budgets become increasingly strained by growing populations, and ageing demographics associated with a greater prevalence of cancer amongst other indications.

Our 203 page report provides 72 tables and 72 figures covering 6 leading submarkets and 13 national markets. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, interviews, trends, opportunities, and revenue predictions. Increasing development and use of biosimilar monoclonal antibodies will increase worldwide sales of such products from 2016 to 2026, our study shows.



Read the full transcript of 2 exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Dr Seoyoung Kim, Assistant Professor of Medicine at Harvard Medical School and Associate Physician, Brigham and Women's Hospital
- Professor Steve Morgan, expert in pharmaceutical policy and Professor of health policy in the School of Population and Public Health, University of British Columbia

Who should read this report: directors of:
- Biosimilars
- Biosimilar monoclonal antibodies
- Monoclonal antibodies
- Regulatory bodies
- Biobetters
- CMOs

What are the prospects in the leading regions and countries?
In our study you will find individual revenue forecasts to 2026 for the leading regional and national markets:
- US
- Japan
- Germany
- France
- UK
- Spain
- Italy
- China
- India
- Brazil
- Russia
- South Korea
- Rest of the World

Why you must buy this totally independent report:
This report features news, insights, the latest developments and an in depth survey of the biosimilar monoclonal antibody market with up-to-date analysis as well as tables, graphs and charts. This report is a vital addition to gaining an understanding of this market sector and will give your company 'the edge' on your competitors. You cannot afford to be without this latest report from visiongain.

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Find in this report:
- Forecast from 2016 – 2026 of the six segments of the market by compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab and Bevacizumab.
- Forecast from 2016 – 2026 of the 17 biosimilar mAbs in the market.
- Profiles of 10 leading companies either with biosimilar mAbs already on the market or in the pipeline in addition to new merger and acquisition analysis.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

Targeted Therapies in Asthma - 2017

Targeted Therapies in Asthma - 2017

  • $ 8355
  • Industry report
  • February 2017
  • by Firstword Pharma

Description As new targeted asthma therapies emerge, is time running out for Xolair? Xolair’s unique position in the targeted asthma treatment market is under threat. Teva’s Cinqair and GSK’s Nucala ...

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

  • $ 4995
  • Industry report
  • April 2017
  • by GBI Research

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs Summary ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.